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Abstract Background The incidence of obesity is increasing and this is of major 
concern as obesity is associated with cardiovascular disease, stroke, type 2 
diabetes, respiratory tract disease, and cancer. Objectives/Methods This evaluation 
is of a Phase II clinical trial with tesofensine in obese subjects. Results After 26 
weeks, tesofensine caused a significant weight loss, and may have a higher maximal 
ability to reduce weight than the presently available anti-obesity agents.  However, 
tesofensine also increased blood pressure and heart rate, and may increase 
psychiatric disorders.  Conclusions It is encouraging that tesofensine 0.5 mg may 
cause almost double the weight loss observed with sibutramine or rimonabant.  As 
tesofensine and sibutramine have similar pharmacological profiles, it would be of 
interest to compare the weight loss with tesofensine in a head-to-head clinical trial 
with sibutramine, to properly assess their comparative potency.   Also, as tesofensine 
0.5 mg increases heart rate, and the incidence of adverse effects such as nausea, 
drug mouth, flatulence, insomnia, and depressed mode, its tolerability needs to be 
further evaluated in large Phase III clinical trials.   
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1. Introduction 
 
The incidence of obesity is increasing worldwide, and in the US, about 100 million 
adults are overweight or obese.  Comorbidities with obesity include cardiovascular 
disease (e.g. hypertension, coronary artery disease, left ventricular hypertrophy), 
stroke, Type 2 diabetes, respiratory tract disease (e.g. obstructive sleep apnoea, 
increased infections, asthma) and cancers.  In 40-year-old male and female 
nonsmokers, it has been suggested that obesity shortens life expectancy by 5.8 and 
7.1 years, respectively [1].  Orlistat and sibutramine are among the drugs presently 
used for weight loss, but they both have a relatively modest effect.  The clinical 
development of the cannabinoid receptor antagonist rimonabant for the treatment of 
obesity has recently been stopped due to safety concerns [2].  Thus, the search for 
safe, effective and potent anti-obesity drugs continues.  
 
In development for Parkinson’s and Alzheimer’s disease, tesofensine was shown to 
reduce body weight [3].  In the total cohort of 740 patients treated with tesofensine, 
over 14 weeks, the weight loss was -0.9%, -1.8%, and -2.8% with tesofensine 0.25, 
0.5 and 1.0 mg, respectively, compared to +0.5% in the placebo group of 228 
patients [3].  Weight loss with tesofensine was similar or slightly higher in the obese 
subgroup; -1.6%, -1.5% and -3.7% with tesofensine 0.25, 0.5 and 1.0 mg, 
respectively, compared to -0.2% in the placebo group [3].  Tesofensine 0.25, 0.5 and 
1 mg increased heart rate by 4.2, 6.0 and 6.8 beats/minute, respectively, without 
altering blood pressure [3].  As a result of this information, a clinical trial of 
tesofensine in obesity was undertaken, and is evaluated here. 
 
2. Methods and results 
 
The methods and results of the Phase II, randomised, double-blind, placebo-
controlled trials showing weight loss with tesofensine [4] are combined in this section.  
The trial was undertaken in 5 Danish obesity management centres, and recruited 
obese subjects (body mass index, BMI from 30 to less than 40 kg/m2) from 18 to 65 
year olds.  There were many exclusion criteria including cardiovascular disease, 
abnormalities in the electrocardiogram, uncontrolled hypertension, and heart rate of > 
90 beats/min. 
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The 203 obese subjects enrolled were predominantly women (~70%), almost all 
white, with a mean BMI of ~35 kg/m2, and waist of ~110 cm.  During a 2-week dietary 
run-in period and during the study, a diet with a daily energy deficit of 300 kcal was 
recommended, as was an increase in physical activity to 30-60 minutes/day.  
Subjects were randomised to placebo or tesofensine at 0.25, 0.5, and 1 mg orally for 
24 weeks.   Subjects attended dietician clinics weekly for 4 weeks, and then every 
second week.  Withdrawals in the placebo, tesofensine 0.25, 0.5 and 1 mg groups 
were of 13, 9, 6, and 14 people. 
 
The primary efficacy endpoint was percent change in body weight, and this was 2.0% 
in the placebo group over 26 weeks.  There was an addition loss of 4.5% (4.5 kg), 
9.2% (9.1 kg), and 10.6% (10.6 kg) in the tesofensine 0.25, 0.5, and 1 mg groups, 
respectively.  After discontinuation of treatment for 8 weeks, there was a weight gain 
of 0.5% in the placebo group, and bigger gains of 0.8%, 2.3%, and 3.8% in the 
tesofensine 0.25, 0.5 and 1 mg groups, respectively. 
 
At 26 weeks, all 3 doses of tesofensine also lowered body fat and waist 
circumference, and decreased total cholesterol to a small extent, but had no 
significant effect on LDL cholesterol or HDL cholesterol levels.   Tesofensine 0.5 and 
1.0 mg lowered the levels of triglycerides.  Tesofensine had no effect on plasma 
glucose, but at 1 mg lowered glycosylated haemoglobin.  
 
Heart rate increased by 4.7, 7.8 and 8.5 beats/min in the tesofensine 0.25, 0.5 and 1 
mg, groups, which was significantly higher than the 0.4 beats/min in the placebo 
group.  The two lower doses of tesofensine had no significant effect on blood 
pressure, but tesofensine 1 mg increased blood pressure by 6.8/5.8 mm Hg, 
compared to 1.3/1.5 mm Hg in the placebo group.  
 
The profile of mood states (POMS brief) was completed at baseline and after weeks 
12 and 24.  This brief tests six mood factors; tension-anxiety, depression-dejection, 
anger-hostility, vigour-activity, fatigue-inertia, and confusion-bewilderment.  
Tesofensine did not alter mood overall, but at I mg increased anger and hostility, and 
at 0.5 and I mg increased confusion.  Tesofensine also improved vigour and activity.   
 
The improvement of total weight-related quality of life-lite (IWQOL-Lite) measures 5 
domains: physical function, self-esteem, sexual life, public distress, and work.  The 
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IWQOL-Lite was improved by 3% by placebo, and this was increased to 17% with 
tesofensine 0.25 mg, and to 21% by tesofensine at both 0.5 mg and 1 mg. 
 
There was no excess of serious adverse effects, but there was an excess of adverse 
effects with tesofensine.  Thus, serious adverse events occurred in 8% of placebo 
subjects, and in 4%, 2% and 6% of subjects treated with tesofensine 0.25, 0.5 and 
1.0 mg, respectively.  Whereas, excess adverse effects with all doses of tesofensine 
included nausea, dry mouth, hard faeces, insomnia, and palpitations.  Nausea was 
observed in 9.6% of subjects in the placebo group, and this was increased to 17.3%, 
20.0%, and 22.4% with tesofensine 0.25, 0.5 and 1 mg, respectively.  Dry mouth was 
observed in 11.5% of the placebo group, but in 23.1%, 42.0% and 59.2% of subjects 
with tesofensine 0.25, 0.5 and 1 mg, respectively.  Insomnia was observed in 1.9% of 
placebo subjects, and this was increased to 3.8%, 12.0% and 26.5% by tesofensine 
0.25, 0.5 and 1 mg, respectively.  In addition, the highest dose of tesofensine (1 mg) 
increased the incidence to abdominal pain (placebo, 0%; tesofensine, 12.2%), 
constipation (7.7% vs 16.3%), sleep phase rhythm disturbances (3.8% vs 12.2%), 
and depression (mood depression and major depression) (0% vs 8.1%). 
 
3. Discussion 
 
The authors point out that the lowest dose of tesofensine 0.25 mg causes a greater 
weight loss than orlistat, and a similar weight loss to sibutramine and rimonabant [4].  
Tesofensine 0.5 mg causes twice the weight loss observed with sibutramine and 
rimonabant [4].  However, the authors do concede that their study is a relatively small 
Phase II study, and that the comparative results need to be borne out by a larger 
Phase III studies, including direct comparison studies [4].  The authors also suggest 
that tesofensine has a lesser effect on blood pressure and heart rate than 
sibutramine for a comparable weight loss [4].   The discussion ends with “We 
conclude that tesofensine 0.5 mg, once daily for 6 months, has the potential to 
produce twice the weight loss as currently approved drugs: however, larger phase III 
studies are needed to substantiate our findings”. 
 
4. Expert opinion 
 
 4.1 Safety of tesofensine in subjects with cardiovascular disease 
Subjects with cardiovascular disease were excluded from this Phase II trial.  Thus, 
the safety of tesofensine in subjects with cardiovascular disease has not been 
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established.  As cardiovascular disease commonly co-exists with obesity, it may be 
appropriate to test tesofensine 0.5 mg in subjects with obesity and mild 
cardiovascular disease (e.g. controlled hypertension) in a Phase II trial with extensive 
cardiovascular monitoring, prior to any Phase III trials. 
 
 4.2 Mechanisms of action of tesofensine and sibutramine 
Tesofensine is described in clinical trials as an inhibitor of the reuptake of 
noradrenaline, dopamine, and 5-hydroxytryptamine [4,5].  The reference for this 
combination of mechanisms is Thatte (2001), who states “NS-2330 is believed to 
increase the activity of dopamine, norepinephrine and acetylcholine by inhibiting the 
re-uptake of the monoamines (dopamine, norepinephrine and serotonin)”, but there is 
no associated reference or evidence to support this [5].  Subsequently, tesofensine 
and its metabolite M1 have been shown to inhibit dopamine uptake with EC50 values 
of 72 nM and 363 nM, respectively [6].  Unpublished data discussed by Lehr et al [6] 
suggests that tesofensine and its metabolite M1 inhibit noradrenaline uptake with IC50 
values of 1.7 nM and 0.6 nM, and 5-hydroxytryptamine (5-HT) uptake with IC50 
values of 11 nM and 2nM, respectively.  This shows that tesofensine shows some 
selectivity in inhibiting noradrenaline and 5-HT uptake over dopamine uptake.  
Sibutramine also shows selectivity in inhibiting noradrenaline and 5-HT over 
dopamine uptake [7].  Thus, it seems to me, that tesofensine will have very similar 
effects to sibutramine in clinical trial for obesity, and this is borne out by the results of 
the Phase II trial with tesofensine.  Although the authors of the Phase II trial with 
tesofensine are suggesting that it causes a similar loss of weight to sibutramine for a 
lesser effect on blood pressure and heart rate, given the similarities in mechanisms 
of action, it will be interesting to see whether this is substantiated in Phase III trial.  
The ideal Phase III clinical trial would be a direct comparison of tesofensine and 
sibutramine. 
   
 4.2 Psychiatric disorders 
In the individual large Rimonabant in Obesity (RIO) clinical trials, there was not an 
increase in psychiatric disorders with rimonabant, but when the trials were combined, 
it was shown that rimonabant caused a small increase in the incidence of anxiety and 
depression [8], which ultimately led to the decision of the manufacturer Sanofi-
Aventis to stop the clinical development of rimonabant for the treatment of obesity [9].  
In the small Phase II trial evaluated here, depressed mood did not occur in the 
placebo group, but was observed in 1.9%, 6.0% and 6.1% of the subjects taking 
tesofensine, 0.25, 0.5 and 1 mg, respectively [4].  Major depression was observed in 
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one subject taking tesofensine, 1 mg [4].  Large Phase III clinical trials are indicated 
to determine whether tesofensine, like rimonabant, causes unacceptable levels of 
psychiatric disorders. 
 
 4.3 Effects on cholesterol levels 
Tesofensine had no effect on LDL cholesterol levels.  The authors of the Phase II 
study compare this with sibutramine and rimonabant, which also have no effect on 
LDL cholesterol [4].  However, the authors failed to mention, that orlistat does 
decrease LDL cholesterol levels [e.g. 10], and that this is an advantage with orlistat 
over sibutramine, rimonabant and tesofensine. 
 
 4.4 No future for tesofensine 1 mg in weight management 
Although tesofensine 1 mg caused a greater weight loss than tesofensine 0.5 mg 
(10.6 kg vs 9.1 kg), this came at the expense of additional adverse effects 
(abdominal pain, constipation, sleep phase rhythm disturbances, and depression) 
and an appreciable rise in blood pressure and heart rate.  These additional adverse 
effects and cardiovascular effects of tesofensine 1 mg are likely to preclude future 
development of this dose for the treatment of obesity. 
 
 4.5 Conclusions 
It is encouraging that tesofensine 0.5 mg may cause almost double the weight loss 
observed with sibutramine or rimonabant.  The safety of tesofensine in subjects with 
cardiovascular disease has not been established, and should be tested in Phase II.  
As tesofensine and sibutramine have similar pharmacological profiles, it would be of 
interest to compare the weight loss with tesofensine in a head-to-head clinical trial 
with sibutramine, to properly assess their comparative potency.   Also, as tesofensine 
0.5 mg increases heart rate and the incidence of adverse effects such as nausea, 
drug mouth, flatulence, insomnia, and depressed mode, its tolerability needs to be 
further evaluated in large Phase III clinical trials.   
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